Radiotherapy refusal in breast cancer with breast-conserving surgery. 2023

Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
Department of Breast Surgery, Women and Children's Hospital, School of Medicine, Xiamen University, No.10, Zhenhai Road, Xiamen, 361003, Fujian Province, China.

BACKGROUND Although radiotherapy after breast-conserving surgery has been the standard treatment for breast cancer, some people still refuse to undergo radiotherapy. The aim of this study is to identify risk factors for refusal of radiotherapy after breast-conserving surgery. METHODS To investigate the trend of refusing radiotherapy after breast-conserving surgery in patients with breast cancer using the Surveillance, Epidemiology, and End Results database. The patients were divided into radiotherapy group and radiotherapy refusal group. Survival results were compared using a multivariate Cox risk model adjusted for clinicopathological variables. Multivariate logistic regression was used to analyze the influencing factors of patients refusing radiotherapy after breast-conserving surgery and a nomogram model was established. RESULTS The study included 87,100 women who underwent breast-conserving surgery for breast cancer between 2010 and 2015. There were 84,948 patients (97.5%) in the radiotherapy group and 2152 patients (2.5%) in the radiotherapy refusal group. The proportion of patients who refused radiotherapy after breast-conserving surgery increased from 2.1% in 2010 to 3.1% in 2015. The Kaplan-Meier survival curve showed that radiotherapy can improve overall survival (p < 0.001) and breast cancer specific survival (p < 0.001) in the patients with breast-conserving surgery. The results of multivariate logistic regression showed that age, income, marital status, race, grade, stage, subtype and chemotherapy were independent factors associated with the refusal of radiotherapy. CONCLUSIONS Postoperative radiotherapy can improve the benefits of breast-conserving surgery. Patients with old age, low income, divorce, white race, advanced stage, and no chemotherapy were more likely to refuse radiotherapy.

UI MeSH Term Description Entries
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015412 Mastectomy, Segmental Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor. Breast-Conserving Surgery,Lumpectomy,Partial Mastectomy,Breast Conservation Therapy,Breast Quadrantectomy,Breast-Sparing Surgery,Limited Resection Mastectomy,Local Excision Mastectomy,Segmentectomy,Surgery, Breast-Conserving,Breast Conservation Therapies,Breast Conserving Surgery,Breast Quadrantectomies,Breast Sparing Surgery,Breast-Conserving Surgeries,Breast-Sparing Surgeries,Conservation Therapies, Breast,Conservation Therapy, Breast,Limited Resection Mastectomies,Local Excision Mastectomies,Lumpectomies,Mastectomies, Limited Resection,Mastectomies, Local Excision,Mastectomies, Partial,Mastectomies, Segmental,Mastectomy, Limited Resection,Mastectomy, Local Excision,Mastectomy, Partial,Partial Mastectomies,Quadrantectomies, Breast,Quadrantectomy, Breast,Segmental Mastectomies,Segmental Mastectomy,Segmentectomies,Surgeries, Breast-Conserving,Surgeries, Breast-Sparing,Surgery, Breast Conserving,Surgery, Breast-Sparing
D016016 Proportional Hazards Models Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time. Cox Model,Cox Proportional Hazards Model,Hazard Model,Hazards Model,Hazards Models,Models, Proportional Hazards,Proportional Hazard Model,Proportional Hazards Model,Cox Models,Cox Proportional Hazards Models,Hazard Models,Proportional Hazard Models,Hazard Model, Proportional,Hazard Models, Proportional,Hazards Model, Proportional,Hazards Models, Proportional,Model, Cox,Model, Hazard,Model, Hazards,Model, Proportional Hazard,Model, Proportional Hazards,Models, Cox,Models, Hazard,Models, Hazards,Models, Proportional Hazard
D053208 Kaplan-Meier Estimate A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995) Kaplan-Meier Survival Curve,Kaplan-Meier Analysis,Kaplan-Meier Survival Curves,Kaplan-Meier Test,Product-Limit Method,Analysis, Kaplan-Meier,Curve, Kaplan-Meier Survival,Curves, Kaplan-Meier Survival,Estimate, Kaplan-Meier,Kaplan Meier Analysis,Kaplan Meier Survival Curve,Kaplan Meier Survival Curves,Kaplan Meier Test,Method, Product-Limit,Methods, Product-Limit,Product Limit Method,Product-Limit Methods,Survival Curve, Kaplan-Meier,Survival Curves, Kaplan-Meier,Test, Kaplan-Meier
D018714 Radiotherapy, Adjuvant Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Radiotherapy,Adjuvant Radiotherapies,Radiotherapies, Adjuvant

Related Publications

Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
May 1996, Journal of the Formosan Medical Association = Taiwan yi zhi,
Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
August 2003, Annals of oncology : official journal of the European Society for Medical Oncology,
Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
January 1995, Acta oncologica (Stockholm, Sweden),
Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
June 2000, European journal of cancer (Oxford, England : 1990),
Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
June 2000, European journal of cancer (Oxford, England : 1990),
Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
June 2000, European journal of cancer (Oxford, England : 1990),
Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
July 2014, Journal of surgical oncology,
Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
November 2020, Breast cancer (Tokyo, Japan),
Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
August 2023, The New England journal of medicine,
Jiameng Liu, and Zhanlin Zhu, and Zhipeng Hua, and Weijie Lin, and Yiyin Weng, and Juli Lin, and Hehui Mao, and Lifen Lin, and Xuming Chen, and Jujiang Guo
June 2010, Technology Evaluation Center Assessment Program. Executive summary,
Copied contents to your clipboard!